Soleno Therapeutics Inc (SLNO)
Official siteBIOTECHNOLOGY
Last updated: May 19, 2026 at 5:00 PM ET
Soleno Therapeutics Inc (SLNO) Financials: Revenue, Profit and Cash Flow
Soleno Therapeutics reported revenue of $190.41M for the fiscal year ended Dec 31, 2025. That year, net income was $20.89M with a net margin of 11.0%, operating cash flow was $46.80M and free cash flow was $46.73M. The quarter ended Mar 31, 2026 had revenue of $94.60M and net income of $31.38M.
Revenue and Margins
The operating margin was 4.9% in the fiscal year ended Dec 2025.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $190.41M | N/A | 98.6% | 4.9% | 11.0% |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Mar 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $190.41M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $2.70M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $187.71M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $40.63M | $78.57M | $25.19M | $15.27M | $21.45M | $23.19M | $16.27M | $7.18M | $3.07M | $2.25M |
| Operating income | $9.41M | -$187.67M | -$41.38M | -$24.40M | -$31.53M | -$36.29M | -$23.49M | -$14.30M | -$12.17M | -$8.32M |
| Net income | $20.89M | -$175.85M | -$38.99M | -$24.07M | -$30.91M | -$24.64M | -$30.77M | -$13.34M | -$15.38M | -$12.07M |
| EBITDA | N/A | N/A | -$39.61M | -$22.40M | -$28.95M | -$22.68M | N/A | -$11.71M | -$11.83M | -$6.72M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $94.60M | $91.73M | $66.02M | $32.66M | $0 | $0 | $0 | $0 | $0 | $3.45M | $0 | $0 |
| Gross profit | $93.41M | $90.87M | $64.88M | $31.96M | $0 | N/A | $0 | $0 | $0 | $2.96M | $0 | $0 |
| Operating income | $31.28M | $39.58M | $22.11M | -$6.53M | -$45.74M | -$59.12M | -$80.21M | -$24.87M | -$23.48M | -$13.91M | -$10.38M | -$8.62M |
| Net income | $31.38M | $43.36M | $26.01M | -$4.71M | -$43.77M | -$55.98M | -$76.62M | -$21.85M | -$21.40M | -$11.30M | -$10.86M | -$8.47M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $50.59M by $19.52M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $563.83M | $330.97M | $180.69M | $26.50M | $35.55M | $64.98M | $38.17M | $43.15M | $39.02M | $5.56M |
| Current assets | $355.81M | $293.89M | $171.36M | $15.65M | $22.42M | $50.24M | $21.14M | $24.67M | $17.99M | $3.80M |
| Cash and equivalents | $70.11M | $87.93M | $169.68M | $14.60M | $21.30M | $49.22M | $20.73M | $23.10M | $17.10M | $2.73M |
| Total liabilities | $113.72M | $85.86M | $23.18M | $16.15M | $17.76M | $19.43M | $23.23M | $12.74M | $12.21M | $2.13M |
| Short-term debt | $726.00K | $526.00K | $273.00K | $155.00K | $282.00K | $139.00K | $305.00K | N/A | N/A | N/A |
| Long-term debt | $49.86M | $49.83M | $0 | N/A | N/A | N/A | N/A | N/A | $0 | $0 |
| Shareholder equity | $450.12M | $245.11M | $157.51M | $10.35M | $17.79M | $45.55M | $14.95M | $30.41M | $26.82M | $3.44M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $608.39M | $563.83M | $599.89M | $332.31M | $318.09M | $330.97M | $296.71M | $304.13M | $168.84M | $180.69M | $63.55M | $30.94M |
| Total liabilities | $112.59M | $113.72M | $105.09M | $92.17M | $85.83M | $85.86M | $32.01M | $23.37M | $25.45M | $23.18M | $40.33M | $18.52M |
| Cash and equivalents | $133.03M | $70.11M | $246.66M | $76.50M | $81.33M | $87.93M | $48.41M | $57.02M | $42.85M | $169.68M | $52.44M | $19.37M |
| Shareholder equity | $495.80M | $450.12M | $494.81M | $240.14M | $232.26M | $245.11M | $264.70M | $280.76M | $143.39M | $157.51M | $23.22M | $12.43M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 99.9% of operating cash flow. Share repurchases came to 214.3% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $46.80M | -$69.10M | -$24.94M | -$20.78M | -$27.77M | -$25.22M | -$17.38M | -$11.68M | -$9.95M | -$13.50M |
| Capital expenditures | $73.00K | $218.00K | $0 | $13.00K | $22.00K | $7.00K | $21.00K | $8.00K | $575.00K | $14.79K |
| Free cash flow | $46.73M | -$69.31M | -$24.94M | -$20.79M | -$27.79M | -$25.23M | -$17.40M | -$11.69M | -$10.53M | -$13.51M |
| Share repurchases | $100.15M | $0 | $0 | N/A | $0 | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | -$201.78M | -$225.68M | $0 | -$13.00K | -$22.00K | -$7.00K | $528.00K | -$180.00K | $154.00K | -$38.68K |
| Financing cash flow | $137.16M | $213.03M | $180.02M | $14.09M | -$128.00K | $53.72M | $14.48M | $17.83M | $24.17M | $10.77M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $25.98M | $48.70M | $43.45M | -$12.61M | -$32.75M | -$23.99M | -$14.93M | -$17.65M | -$12.53M | -$6.31M | -$6.33M | -$5.57M |
| Capital expenditures | $40.00K | $58.00K | $1.00K | $9.00K | $5.00K | $8.00K | $191.00K | $8.00K | $11.00K | $0 | $0 | $0 |
| Free cash flow | $25.94M | $48.65M | $43.45M | -$12.62M | -$32.76M | -$24.00M | -$15.12M | -$17.66M | -$12.54M | -$6.31M | -$6.33M | -$5.57M |
Frequently Asked Questions About SLNO
What is Soleno Therapeutics' annual revenue?
Soleno Therapeutics reported revenue of $190.41M for the fiscal year ended Dec 31, 2025.
Is Soleno Therapeutics profitable?
Yes. Soleno Therapeutics reported net income of $20.89M for the fiscal year ended Dec 31, 2025, with a net margin of 11.0%.
How much free cash flow does SLNO generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $46.80M minus capital expenditures of $73.00K produced free cash flow of $46.73M.
How much debt does Soleno Therapeutics have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $49.86M, short-term debt of $726.00K and cash and equivalents of $70.11M.
What is SLNO's profit margin?
For the fiscal year ended Dec 31, 2025, Soleno Therapeutics reported gross margin of 98.6%, operating margin of 4.9% and net margin of 11.0%.
SLNO pages: Overview, Financials